Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | DAPK3 | O43293 | 12/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15512479 | 1.00 | MAPK1 (0.66) | MAPK1SMN1; SMN2DAPK3KDM4EGAA | |
| SCHEMBL13205734 | 1.00 | MAPK1 (0.66) | MAPK1SMN1; SMN2DAPK3KDM4EGAA | |
| SCHEMBL15512630 | 0.80 | KDM4E (0.52) | MAPK1SMN1; SMN2DAPK3KDM4EGAA | |
| SCHEMBL15512629 | 0.80 | KDM4E (0.52) | MAPK1SMN1; SMN2DAPK3KDM4EGAA | |
| SCHEMBL13206232 | 0.80 | KDM4E (0.52) | MAPK1SMN1; SMN2DAPK3KDM4EGAA | |
| SCHEMBL14984125 | 0.79 | KDM4E (0.48) | MAPK1SMN1; SMN2DAPK3KDM4EGAA | |
| SCHEMBL24241532 | 0.79 | MAPT (0.49) | MAPK1SMN1; SMN2KDM4EPOLBNOTUM | |
| SCHEMBL29518116 | 0.79 | MAPT (0.49) | MAPK1SMN1; SMN2KDM4EPOLBNOTUM | |
| SCHEMBL5633770 | 0.78 | SMN1; SMN2 (1.00) | MAPK1SMN1; SMN2DAPK3KDM4EGAA | |
| SCHEMBL5633766 | 0.78 | SMN1; SMN2 (1.00) | MAPK1SMN1; SMN2DAPK3KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018238-B2 | Inhibitor of casein kinase 1δ and casein kinase 1ε | PHARMADESIGN, INC. (JP) | 2015-04-28 | — | — | US | claimed |
| EP-2397481-B1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON | PHARMADESIGN INC (JP) | 2014-03-12 | — | — | EP | claimed |
| EP-2397481-A1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON | Pharmadesign, Inc. (JP) | 2011-12-21 | — | — | EP | claimed |
| US-20110294857-A1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON | NB HEALTH LABORATORY CO. LTD. (JP) | 2011-12-01 | — | — | US | claimed |
| US-9018238-B2 | Inhibitor of casein kinase 1δ and casein kinase 1ε | PHARMADESIGN, INC. (JP) | 2015-04-28 | — | — | US | disclosed |
| EP-2397481-B1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON | PHARMADESIGN INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-2397481-A1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON | Pharmadesign, Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20110294857-A1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON | NB HEALTH LABORATORY CO. LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294857-A1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON | CSNK1A1, CSNK1G1, CSNK2A1 | MAPK1 180/4885SMN1; SMN2 1727/4885DAPK3 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.